TY - JOUR T1 - IL-18 AND ADROPIN LEVELS IN PATIENTS WITH ACUTE ISCHEMIC STROKE TT - AKUT İSKEMİK İNMELİ HASTALARDA IL-18 VE ADROPİN DÜZEYLERİ AU - Eren, Alper AU - İyigün, İbrahim PY - 2022 DA - June Y2 - 2021 DO - 10.17343/sdutfd.1002269 JF - Medical Journal of Süleyman Demirel University JO - Med J SDU PB - Süleyman Demirel University WT - DergiPark SN - 1300-7416 SP - 187 EP - 195 VL - 29 IS - 2 LA - en AB - ObjectiveAtherosclerosis, one of the prominent factors causingdysfunctional vascular events in stroke patients,is a multi-factorial and complex process in whichendothelial dysfunction and vascular inflammationplay significant roles. This study aimed to investigatethe relationships between serum levels of IL-18 andadropin, associated with endothelial dysfunction andinflammatory processes in acute ischemic strokepatients, with epidemiological, clinical, radiologicalfindings and stroke severity.Materials and MethodsSixty-one patients diagnosed with acute ischemicstroke and 30 healthy individuals were included in thestudy as the patient and control groups. In the patientgroup, the stroke sub-groups and severity weredetermined etiologically and clinically. Venous bloodsamples were obtained within the first 24 hours in thepatient group, and at any time in the control group,their serums were separated and stored at -80°C. IL-8and adropin levels were determined using the ELISAmethod. The relationships between patient andcontrol groups’ IL-18 and adropin levels and ischemicstroke were analyzed statistically.ResultsThe adropin level was statistically significantlylower in the patient group than the control group(398.01±403.51 and 509.42±1492.89, respectively;p=0.041). The IL-18 levels of the study and controlgroups were similar (24.87±14.26 and 21.11±14.93,respectively; p=0.112). There was no relationshipbetween the IL-18 and adropin levels determinedwith stroke risk factors, stroke sub-groups, and strokeseverity.ConclusionThese results showed that low adropin levels could beused to indicate atherosclerosis in the risk predictionscales of ischemic stroke. The absence of a differencebetween the patient group with acute ischemic strokeand the control group regarding the first 24-hour meanserum IL-18 level suggested that IL-18 could playa role as a late-stage cytokine in ischemia-relatedinflammation. KW - ischemic stroke KW - adropin KW - IL-18 KW - inflammation KW - endothelial dysfunction N2 - Amaçİnmeli hastalarda disfonksiyonel vasküler olaylara yolaçan önde gelen faktörlerden bir tanesi olan ateroskleroz;endotelyal disfonksiyon ve vasküler inflamasyonunönemli bir rol oynadığı çok faktörlü ve kompleksbir süreçtir. Biz bu çalışmada endotel disfonksiyonuve inflamatuar süreçlerle ilişkisi gösterilmiş olan IL-18 ve adropininin akut iskemik inme hastalarındakiserum düzeyleri ile epidemiyolojik, klinik, radyolojikbulgular ve inme şiddeti arasındaki ilişkiyi araştırmayıamaçladık.Gereç ve YöntemÇalışmamıza akut iskemik inme tanısı konulan 61hasta ve kontrol grubu olarak 30 sağlıklı birey alındı.Hasta grubunda etiyolojik ve klinik olarak inme altgrupları ve inme şiddeti belirlendi. Hasta grubundanilk 24 saatte, kontrol grubundan herhangi bir zamandavenöz kan örnekleri alınarak serumları ayrıldı ve-80⁰C’de saklandı. ELISA yöntemi kullanılarak IL-8 veadropin düzeyleri belirlendi. Hasta ve kontrol gruplarınınIL-18 ve adropin düzeyleri ile iskemik inme arasındakiilişkiler istatistiksel olarak analiz edildi.BulgularAdropin düzeyi hasta grubunda kontrol grubuna göreistatistiksel olarak anlamlı derecede düşüktü (sırasıyla398.01±403.51 ve 509.42±1492.89; p=0.041). Çalışmave kontrol gruplarının IL-18 düzeyleri benzerdi(sırasıyla 24.87±14.26 ve 21.11±14.93; p=0.112).İnme risk faktörleri, inme alt grupları ve inme şiddetiile belirlenen IL-18 ve adropin düzeyleri arasında ilişkiyoktu.SonuçBu bulgular, düşük adropin düzeylerinin aterosklerozgöstergesi olarak iskemik inme risk tahmini ölçeklerindekullanılabileceğini göstermiştir. Akut iskemik inmelihasta grubu ile kontrol grubu arasında ortalamaserum IL-18 düzeyi açısından fark olmaması, IL-18'iniskemiye bağlı inflamasyonda geç dönem bir sitokinolarak rol oynayabileceğini düşündürmüştür. CR - 1. Monica, W. H. O. & Project Principal Investigators. The World Health Organization MONICA project (monitoring trends and determinants in cardiovascular disease): a major international collabaration. Journal of clinical epidemiology. Oxford; New York: Pergamon Press 1988; vol. 41, no. 2. CR - 2. Ihle-Hansen H, Thommessen B, Wyller TB, Engedal K, Fure B. Risk factors for and incidence of subtypes of ischemic stroke. Functional neurology 2012; 27: 1-35. CR - 3. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003; 4(5): 399-415. CR - 4. Basic Kes V, Simundic AM, Nikolac N, et al. Pro- inflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke outcome. Clin Biochem. 2008; 41(16-17): 1330-4. CR - 5. Dinarello CA. Novel targets for interleukin 18 binding protein. Ann Rheum Dis. 2001; 60[Suppl 3]:18–24. CR - 6. Gürkaş E, Orhan G, Ak F. The relationship of IL-18 levels with early and late clinical findings and infarct volume in patients with acute ischemic stroke. Turkish Journal of Cerebrovascular Diseases 2012; 18(1): 10-15. CR - 7. Mallat Z, Corbaz A, Scoazec A, et al. Expression of interleukin- 18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598 –1603. CR - 8. Blankenberg S, Luc G, Ducimetiere P, et al. Interleukin-18 and risk of coronary heart disease in European men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003; 108: 2453– 2459. CR - 9. Stott DJ, Welsh P, Rumley A, et al. Adipocytokines and risk of stroke in older people: a nested case-control study. Int J Epidemiol. 2009; 38:253–61. CR - 10. Zaremba J, Losy J. Interleukin-18 in acute ischaemic stroke patients. Neurol Sci. 2003; 24:117–24. CR - 11. Sarchielli P, Nardi K, Chiasserini D, et al. Immunological profile of silent brain infarction and lacunar stroke. PLoS One. 2013; 8(7):e68428. CR - 12. Bossù P, Salani F, Cacciari C, et al. Disease outcome, alexithymia and depression are differently associated with serum IL-18 levels in acute stroke. Curr Neurovasc Res. 2009; 6:163–70. CR - 13. Yu XH, Qian K, Jiang N, et al. ABCG5/ABCG8 in cholesterol excretion and atherosclerosis. Clin. Chim. Acta 2014; 428: 82–88. CR - 14. Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8:468–81. CR - 15. Shahjouei S, Ansari S, Pourmotabbed T, Zand R. Potential roles of adropin in central nervous system: review of current literature. Front. Mol. Biosci. 2016; 3: 25. CR - 16. Lovren F, Pan Y, Quan A, et al. Adropin is a novel regulator of endothelial function. Circulation 2010; 122 (11 Suppl. 1): 185- 192. CR - 17. Kathir K, Adams MR. Endothelial dysfunction as a predictor of acute coronary syndromes. Semin Vasc Med. 2003;3:355–62. CR - 18. Wu L, Fang J, Chen L, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med. 2014;52:751–8. CR - 19. Topuz M, Celik A, Aslantas T, at al. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J. Investig. Med. 2013; 61 (8): 1161–1164. CR - 20. Esper RJ, Nordoby RA, Vilarino JO, et al. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 2006; 5: 4. CR - 21. Zhang C, Zhao L, Xu W, et al. Correlation of serum adropin level with coronary artery disease. Zhonghua Yi Xue Za Zhi 94 2014; 94(16): 1255–1257. CR - 22. Yu HY, Zhao P, Wu MC, et al. Serum adropin levels are decreased in patients with acute myocardial infarction. Regul. Pept. 2014; 190–191: 46–49. CR - 23. Gunaydin M, Aygun A, Usta M, at al. Serum adropin levels in patients with acute ischemic stroke. Medicine 2019; 8(3): 698- 702. CR - 24. Yang C, DeMars KM, Candelario-Jalil E. Abstract TP277: Adropin is Profoundly Neuroprotective in Experimental Ischemic Stroke. Stroke 2017; 48(suppl_1), ATP277-ATP277. CR - 25. Yang C, Sanz BD, DeMars KM, at al. Abstract WP315: Neuroprotective Effects of Endogenous Adropin in Experimental Ischemic Stroke. Stroke 2020; 51(Suppl_1), AWP315- AWP315. CR - 26. Georgakis MK, Gill D, Rannikmäe K, at al. Genetically Determined Levels of Circulating Cytokines and Risk of Stroke. Circulation. 2019; 139:256–68. CR - 27. Yuen CM, Chiu CA, Chang LT, et al. Level and value of interleukin- 18 after acute ischemic stroke. Circ J. 2007; 71(11): 1691-6. CR - 28. Ormstad H, Aass HCD, Lund-Sørensen N, at al. Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume. Journal of neurology 2011; 258(4): 677-685. CR - 29. Hao Y, Ding J, Hong R, at al. Increased interleukin-18 level contributes to the development and severity of ischemic stroke. Aging (Albany NY) 2019; 11(18): 7457. CR - 30. Jander S, Schroeter M, Stoll G. Interleukin-18 expression after focal ischemia of the rat brain: association with the late-stage inflammatory response. J Cereb Blood Flow Metab 2002; 22: 62–70. CR - 31. Wheeler RD, Boutin H, Touzani O, et al. No Role for Interleukin- 18 in Acute Murine Stroke-Induced Brain Injury. J Cereb Blood Flow Metab 2003; 23(5): 531-5. UR - https://doi.org/10.17343/sdutfd.1002269 L1 - https://dergipark.org.tr/en/download/article-file/2000438 ER -